Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)
about
Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumorsAnalysis of the genome to personalize therapy for melanomaThe value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancersCortactin phosphorylated by ERK1/2 localizes to sites of dynamic actin regulation and is required for carcinoma lamellipodia persistenceA meta-analysis approach for characterizing pan-cancer mechanisms of drug sensitivity in cell linesHER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1BThe Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivitySystematic identification of genomic markers of drug sensitivity in cancer cellsAnalysis of mRNA profiles after MEK1/2 inhibition in human pancreatic cancer cell lines reveals pathways involved in drug sensitivity.A rank-based transcriptional signature for predicting relapse risk of stage II colorectal cancer identified with proper data sources.A new molecular signature method for prediction of driver cancer pathways from transcriptional data.Cross-species analysis of genetically engineered mouse models of MAPK-driven colorectal cancer identifies hallmarks of the human disease.Panel based MALDI-TOF tumour profiling is a sensitive method for detecting mutations in clinical non small cell lung cancer tumour.Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma.Identification of transcriptional regulatory networks specific to pilocytic astrocytoma.Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines.Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells.Dual-specificity MAP kinase phosphatases (MKPs): shaping the outcome of MAP kinase signalling.Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell linesPhase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.Integrating phenotypic small-molecule profiling and human genetics: the next phase in drug discovery.Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.Stimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines.β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomasTargeted agents for the treatment of metastatic melanoma.STAT3 mediates resistance to MEK inhibitor through microRNA miR-17.Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer.High-dimensional omics data analysis using a variable screening protocol with prior knowledge integration (SKI)A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome.Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors.MEK1/2 inhibition enhances the radiosensitivity of cancer cells by downregulating survival and growth signals mediated by EGFR ligands.A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC.RAF265 inhibits the growth of advanced human melanoma tumors.MEK inhibition affects STAT3 signaling and invasion in human melanoma cell linesOncogenic NRAS signaling differentially regulates survival and proliferation in melanomaPreclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients.Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells.
P2860
Q24294914-8FD7591D-747C-495F-9B47-C227ABDEDB11Q24601008-722B8B3D-AA6A-4AD8-A971-721653D3D32FQ26747403-904666F5-392C-4AD7-A7E5-8260F595B2A3Q27316921-A50F3D5D-1E7E-4643-89AF-952DD23780D6Q28540936-2A18A3C4-D49D-4515-8DD6-8EE71AF6DB92Q28551145-720501DB-FAE2-4F63-B66A-D4FF731890ACQ29547693-0FC3DF70-6FA1-45C1-9E5A-505F326BF0F5Q29547695-8E651A9F-AA12-4FA4-8778-67A71CC67C66Q30409158-BCEE76E4-7704-40CF-8F8B-E9AEFB197109Q31056926-C6D63F1C-3A5D-478A-8A01-6A625BF3F3B2Q31081853-3A9B9EF1-CB5C-41FE-B733-EB657CBE9CF2Q33677196-0D940649-D88E-4B8B-A373-0DE77624A88FQ33793611-64495F67-E18C-400F-AA96-8A21285475C0Q33861173-D36BAB6D-4F1A-4A2E-930E-659C176B6F87Q33957184-42098B9B-5387-44D8-8420-0EBE23F937F5Q34129528-57179BEC-DEA0-44C3-8A34-3F68A01296CBQ34272199-4E67102E-93FB-4757-B456-0F93114E237AQ34273541-E03118FE-C3CE-477A-852B-D82C92655FFFQ34289063-25F81148-A6EA-49C0-88D6-4851940BB308Q34526671-D30E8B18-BC4A-4320-80D8-FD1842365182Q34633455-10326627-D5E8-406A-8505-36324C915766Q34797680-1E01D40B-18F1-46E8-B622-141CF4B68FC7Q35023456-21E13449-75E1-42AA-A771-27D9CDD68A49Q35079398-03C12849-F96E-4D4A-94B0-8A6C2E93B600Q35610049-C74E0230-F657-4C93-8262-60679D297598Q35621787-DB814957-F40A-42E9-83E3-1BF5C6A74B45Q35822194-6A1A2436-C3A0-4076-B471-AAEF5809CEEAQ36083385-040D92E9-004F-49A5-8538-2B2AED0C6D4BQ36166893-596C1195-0F7D-48B0-8FDC-7E251DE79EAFQ36268787-22A98A38-2319-40CB-B125-65267590C0EEQ36714160-DB97B23F-0E12-4B1E-956B-CC7B6B72577DQ36900522-E862D1B6-55E1-45EC-9766-A226DC98590EQ36976683-57037405-AA58-44C9-8436-33AE21139BC8Q37017721-DE9DACFE-6A55-4627-9397-29AD6DBC2C60Q37047974-EFC6F33A-993D-4A86-A912-D7E8A65A8CAFQ37161421-F11D6697-6779-469A-8A9A-7738C152A2D0Q37183820-A2C90D1A-6EB0-44B7-9109-F0F06A7361E4Q37421431-339B1468-E79D-41C4-B779-B89AB022DA7EQ37514034-2F73B5CD-1880-41B2-B016-B58FC72CB053Q37529969-6B2D6631-AE5B-477D-BB54-EC09009638A8
P2860
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Transcriptional pathway signat ...... ponse to selumetinib (AZD6244)
@en
type
label
Transcriptional pathway signat ...... ponse to selumetinib (AZD6244)
@en
prefLabel
Transcriptional pathway signat ...... ponse to selumetinib (AZD6244)
@en
P2093
P2860
P50
P1433
P1476
Transcriptional pathway signat ...... ponse to selumetinib (AZD6244)
@en
P2093
Alexander Graham
Andrew Cassidy
Barry S Taylor
Carolyn Haggerty
Chris Harbron
Christine A Pratilas
Christine Chresta
Darren Hodgson
David B Solit
P2860
P304
P356
10.1158/0008-5472.CAN-09-1577
P407
P577
2010-03-09T00:00:00Z